Make Better Decisions - Finding and Evaluating Generic and Branded Drug Market Entry Opportunities

Get the Book: Make Better Decisions

Finding and Evaluating Generic and Branded Drug Market Entry Opportunities

PDF eBook: Just $10 Get Print Book on Amazon

Serving hundreds of leading biopharmaceutical companies globally:

Julphar
Harvard Business School
Covington
UBS
QuintilesIMS
Chubb

Generated: August 18, 2019

DrugPatentWatch Database Preview

GLATIRAMER ACETATE Drug Profile

  Try a free trial


See Plans and Pricing

« Back to Dashboard

When do Glatiramer Acetate patents expire, and when can generic versions of Glatiramer Acetate launch?

Glatiramer Acetate is a drug marketed by Mylan and is included in two NDAs.

The generic ingredient in GLATIRAMER ACETATE is glatiramer acetate. There are five drug master file entries for this compound. Three suppliers are listed for this compound. Additional details are available on the glatiramer acetate profile page.

Drug patent expirations by year for GLATIRAMER ACETATE
Medical Subject Heading (MeSH) Categories for GLATIRAMER ACETATE
Synonyms for GLATIRAMER ACETATE
147245-92-9
5M691HL4BO
943513-95-9
AB0110033
AC-28732
AC1MIXQC
acetic acid; (2S)-2-amino-3-(4-hydroxyphenyl)propanoic acid; (2S)-2-aminopentanedioic acid; (2S)-2-aminopropanoic acid; (2S)-2,6-diaminohexanoic acid
AM84438
AN-6995
C9H11NO3.C6H14N2O2.
COP-1
Copaxone
Copolymer 1
Copolymer-1
DTXSID30163637
FHEAIOHRHQGZPC-KIWGSFCNSA-N
FT-0686728
Glatiramer acetate [USAN:BAN]
Glatirameracetat
Glatopa
L-alanine compound with L-glutamic acid and L-lysine and L-tyrosine and acetic acid (1:1:1:1:1)
L-Glutamic acid peptide with L-alanine, L-lysine and L-tyrosine, acetate (salt)
LS-186971
LS-71889
Protiramer
TV 5010
UNII-5M691HL4BO
Y0429

US Patents and Regulatory Information for GLATIRAMER ACETATE

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Exclusivity Expiration
Mylan GLATIRAMER ACETATE glatiramer acetate INJECTABLE;SUBCUTANEOUS 091646-001 Oct 3, 2017 AP RX No No ➤ Sign Up ➤ Sign Up ➤ Sign Up
Mylan GLATIRAMER ACETATE glatiramer acetate INJECTABLE;SUBCUTANEOUS 206936-001 Oct 3, 2017 AP RX No No ➤ Sign Up ➤ Sign Up ➤ Sign Up
Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Exclusivity Expiration

Subscribe to access the full database, or try a Free Trial

Make Better Decisions: Try a trial or see plans & pricing

Serving hundreds of leading biopharmaceutical companies globally:

Johnson and Johnson
Healthtrust
Queensland Health
Chinese Patent Office
McKesson
US Army

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.